Navigation Links
Transcept Pharmaceuticals to Present at Lazard Capital Markets Healthcare Conference on November 17
Date:11/10/2009

RICHMOND, Calif., Nov. 10 /PRNewswire-FirstCall/ -- Transcept Pharmaceuticals, Inc. (Nasdaq: TSPT) today announced that it will present at the Lazard Capital Markets 6th Annual Healthcare Conference on Tuesday, November 17, at 2:10 p.m. Eastern Standard Time. A live audio webcast and replay of the presentation will be available on the Transcept investor webpage at www.transcept.com.

About Transcept

Transcept Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in neuroscience. The most advanced Transcept product candidate is Intermezzo® (zolpidem tartrate sublingual tablet), for which a New Drug Application (NDA) was submitted to the U.S. Food and Drug Administration (FDA) in September 2008 seeking approval as a prescription sleep aid for use in the middle of the night at the time a patient awakens and has difficulty returning to sleep. In October 2009, Transcept received a Complete Response Letter from the FDA on the Intermezzo® NDA and is working to respond to issues raised in the letter. Transcept and Purdue Pharmaceutical Products, L.P. have entered into a collaboration agreement for the development and commercialization of Intermezzo® in the United States. For further information, please visit the company's website at: www.transcept.com.

    Contact:

    Transcept Pharmaceuticals, Inc.
    Greg Mann
    Director, Corporate Communications
    (510) 215-3567
    gmann@transcept.com

SOURCE Transcept Pharmaceuticals, Inc.


'/>"/>
SOURCE Transcept Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Transcept Pharmaceuticals to Report Third Quarter 2009 Results and Host Conference Call on November 12
2. Transcept Pharmaceuticals Receives Complete Response Letter from FDA on Intermezzo(R) New Drug Application
3. Transcept Pharmaceuticals to Report First Quarter 2009 Results
4. Transcept Pharmaceuticals Submits New Drug Application for Intermezzo(R) for Treatment of Middle-of-the-Night Awakenings
5. Transcept Pharmaceuticals Announces Intent to Submit New Drug Application for Intermezzo(R) in Third Quarter 2008
6. Vion Pharmaceuticals Reports 2009 Third Quarter and Nine-Month Results
7. Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2009 Financial Results
8. Arena Pharmaceuticals Announces Third Quarter 2009 Financial Results and Recent Developments
9. ISTA Pharmaceuticals Highlights Bepreve(TM) Clinical Data at the 2009 Annual Meeting of the American College of Allergy, Asthma & Immunology (ACAAI)
10. Bend Research and Vertex Pharmaceuticals Enter New Scientific Collaboration
11. DUSA Pharmaceuticals to Present at the Merriman Curhan Ford Investor Summit 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/5/2017)... 2017 Oramed Pharmaceuticals Inc. (NASDAQ: ... pharmaceutical company focused on the development of oral drug ... its meeting with the U.S. Food and Drug Administration ... At the meeting, ... for submission of ORMD-0801, would be a Biologics License ...
(Date:8/31/2017)... PM360,s annual Innovations Issue, published in ... innovations happening across the industry. Established six years ago, ... providing a comprehensive look at the newest and most ... innovative companies, startups, divisions, products, services, and strategies from ... "Everyone in this industry wants to do better—in all ...
(Date:8/28/2017)... Aesculight ®, a division of LightScalpel ®, LLC, is announcing its ... 20 years of American veterinary laser surgery innovation, Aesculight® is revolutionizing veterinary ... ... with his new VetScalpel laser. Dr. Duclos practices veterinary dermatology at the ... ...
Breaking Medicine Technology:
(Date:9/20/2017)... ... September 20, 2017 , ... Compliancy Group is ... software, The Guard®, has helped another long-time client pass their Department of Health ... satisfy the law. , Thanks to the help of the Compliancy Group's Audit ...
(Date:9/20/2017)... ... September 20, 2017 , ... The Centers for Medicare ... Rule that it will transition to using only Worksheet S-10 to distribute Disproportionate Share ... of three live 60-minute complimentary webinars on October 17, 2017 at 2 ...
(Date:9/20/2017)... (PRWEB) , ... September 20, 2017 , ... ... for overcoming addiction. “RECYCLED Ezekiel's Plan for Freedom from ADDICTION” is the ... extensive background in the field of addiction and homeless services, including more than ...
(Date:9/20/2017)... ... ... “The Foggy Road to Moorwick”: the adventures of a young Scottish girl yearning to see ... Liston, a busy mother of five who used her time waiting for children to finish ... over twenty years. It was a way to give some meaning to the hours ...
(Date:9/19/2017)... ... September 19, 2017 , ... Only a few physicians ... include Brevard’s own Ross A. Clevens, MD, FACS . The founder and medical ... Plastic and Reconstructive Surgeon who trained at Yale, Harvard and the University of Michigan. ...
Breaking Medicine News(10 mins):